Creatine kinase Market, by Type (MM, BB, MB, MiMi), End Use (Hospital, Laboratory, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027

The creatine kinase market was valued at $334.6 million in 2023 and is estimated to reach $887.1 million by 2033, exhibiting a CAGR of 10.3% from 2024 to 2033.

Market Introduction

Creatine kinase (CK) is an enzyme primarily found in the heart, skeletal muscles, and brain. It is released into the bloodstream when these tissues are damaged. CK plays a crucial role in converting creatine into phosphocreatine, a high-energy molecule used by the body for energy production. High CK levels in blood tests indicate muscle damage or degeneration, either chronic or acute. A CK test measures the amount of this enzyme in the blood and is commonly used to diagnose and monitor various muscle-related issues such as diseases, injuries, and inflammation. It is often performed along with other tests to provide a comprehensive assessment of muscular health.

Key Takeaways

• The creatine kinase market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major creatine kinase industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• In May 2023, a clinico-biochemical study published in Springer Nature, comparing serum levels of urea, uric acid, and creatine kinase in oral cancer and potentially malignant disorders (OPMDs) revealed significant differences. Patients with OPMDs and oral cancer showed higher urea levels, lower uric acid levels, and higher creatine kinase levels compared to healthy controls. These findings suggest the potential of these markers in diagnosing and monitoring OPMDs and oral cancer.
• In July 2021, the research study published in the journal Nature, identified creatine kinase B (CKB) as a crucial regulator of thermogenesis in adipocytes. In both mouse and human adipocytes, CKB is significantly induced by thermogenic stimuli. Adipocyte-specific deletion of CKB in mice leads to reduced thermogenic capacity, increased susceptibility to obesity, and disrupted glucose homeostasis. These findings highlight CKB's essential role in controlling the futile creatine cycle, shedding light on potential targets for combating obesity and metabolic diseases.

Key Market Dynamics

The creatine kinase market growth is driven by its pivotal role in detecting and monitoring various muscle-related conditions. Creatine kinase (CK) tests are essential for diagnosing myositis, myopathies like muscular dystrophy, and rhabdomyolysis, facilitating timely intervention and treatment. In addition, CK tests are helpful in monitoring muscle damage over time. The market growth is further driven by the utility of CK tests in combination with other blood chemistry tests, providing comprehensive insights regarding muscle health and potential kidney damage.

The limitations associated with creatine kinase (CK) involve its lack of specificity, as increased levels may arise from conditions beyond muscular disorders. Furthermore, CK concentrations can be influenced by factors like ethnicity, gender, age, and physical activity levels. Consequently, CK testing may not consistently indicate disease severity or progression, highlighting the need for complementary diagnostic methods.

The creatine kinase market is undergoing significant advancements with new product approvals and technological advancements that present opportunities in diagnosing and monitoring muscle diseases associated with muscle atrophy. For instance, on June 13, 2024, the Food and Drug Administration (FDA) accelerated approval of Augtyro (repotrectinib) for neurotrophic tyrosine receptor kinase (NTRK) positive solid tumors highlighting significant opportunities in the creatine kinase market. CK serves as a crucial biomarker in monitoring patients treated with Augtyro, particularly for myalgia with CK elevation. This highlights a rising demand for CK testing in oncology settings.

Global Creatine Kinase Market Ecosystem Analysis

Neuromuscular disorders present a significant burden globally, impacting individuals across all age groups and leading to major disabilities over time. Accurate diagnosis of these disorders is challenging and often requires a multidisciplinary approach, incorporating clinical signs, symptoms, laboratory tests, electrophysiological studies, histopathology, and imaging.

A study conducted at a tertiary care center in India in 2023, reviewed 112 muscle biopsies of patients suspected to have neuromuscular disorders. Results showed that inflammatory myopathies were the most common, followed by muscular dystrophies and neurogenic atrophy. Histological evaluation provided definitive diagnoses in a significant proportion of cases, highlighting the importance of muscle biopsy in guiding treatment decisions and improving patient outcomes. However, the study also revealed challenges in diagnosis, including false positive and false negative results, highlighting the need for careful interpretation of biopsy findings in combination with clinical data.

These findings emphasize the importance of integrating clinical, laboratory, and histopathological assessments to achieve accurate diagnoses and tailor treatment strategies effectively.

Market Segmentation

The creatine kinase market is segmented into product, sample type, end user, and region. On the basis of product, the market is divided into instruments and reagents & kits. On the basis of sample type, the market is classified into blood, urine, and others. On the basis of end user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

In Europe, the approval process for Duvyzat (givinostat), a promising nonsteroidal therapy for Duchenne muscular dystrophy (DMD), is currently underway following the FDA's recent approval in the U.S. as of June 21, 2024. DMD affects approximately 0.5 in 10,000 individuals across Europe, totaling about 25,000 people. The European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) are actively evaluating the drug's application, although specific timelines are yet to be confirmed. In such cases, creatine kinase (CK) continues to play a critical role in assessing disease progression and treatment efficacy for patients and healthcare providers awaiting potential access to new therapeutic options like givinostat.

Efforts to improve diagnostic timelines are crucial, as earlier detection can facilitate prompt intervention and management. In Austria, where recent data from a survey published in National Organization for Rare Disorders (NORD) comprised of 57 patients that showed an average age of DMD symptom onset of 3.1 years, diagnosis was often prompted by hyperCKemia detection in infancy or early childhood.

Comparatively, Germany's TREAT-NMD DMD patient registry reported similar symptom onset at 3.06 years, with a shorter average diagnosis time of 4.7 months. TREAT-NMD is an international network of researchers, clinicians, and patient organizations dedicated to advancing research and treatment for neuromuscular diseases. This highlights efforts within European countries to expedite diagnoses, crucially aided by genetic testing and early clinical recognition.

Creatine kinase (CK) levels, elevated due to muscle breakdown, serve as a pivotal biomarker aiding in DMD diagnosis, especially when asymptomatic or during early stages. Monitoring CK levels informs disease progression and response to treatments like corticosteroids, which remain central to managing DMD symptoms and delaying muscle degeneration.

Competitive Landscape

The major players operating in the creatine kinase market include BBI Solutions, Boditech Med Inc., Novus Biologicals, Thermo Fisher Scientific Inc., Abbott, Danaher, DiaSys Diagnostic Systems GmbH, PerkinElmer Inc., Randox Laboratories Ltd., and others.

Recent Key Strategies and Developments

• In September 2022, Edgewise Therapeutics reported positive interim results from the ARCH study of EDG-5506 in Becker muscular dystrophy patients. Significant improvements in North Star Ambulatory Assessment (NSAA) and reductions in serum CK and Troponin (TNNI2) levels were observed. EDG-5506 demonstrated good tolerability with no serious adverse events. These findings support its potential to alter disease progression.
• In October 2020, the research study published in ALS News Today, leading medical news platform, stated that the elevated creatine kinase levels, indicative of muscle damage, are associated with better survival rates in amyotrophic lateral sclerosis (ALS) patients. The findings suggest that monitoring this protein may help predict disease progression and patient outcomes. Elevated serum creatine kinase levels were observed in ALS patients compared to healthy controls, with higher levels correlating with longer disease duration.

Key Sources Referred

1. National Institutes of Health (NIH)
2. The Neuromuscular Disease Foundation
3. World Health Organization (WHO)
4. WebMD LLC.
5. National Library of Medicine
6. Centers for Disease Control and Prevention

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the creatine kinase market segments, current trends, estimations, and dynamics of the creatine kinase market analysis from 2023 to 2033 to identify the prevailing creatine kinase market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the creatine kinase market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global creatine kinase market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global creatine kinase market trends, key players, market segments, application areas, and market growth strategies.

In addition to providing a detailed analysis of key players in the global market, the report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.